TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06608264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress ball intervention
Description: Stress ball intervention; A medium hard, round, high quality stress ball of the same brand will be given to the patient\&amp;#39;s actively used hand 1-2 minutes before starting the continuous passive movement exercise by the researcher.The patient will be asked to squeeze and relax the stress ball for a count of 5 during continuous passive movement.After squeezing the stress ball, the patient should count to 5 and then relax it.The patient will be asked to continue this process until the continuous passive movement exercise is completed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand holding intervention
Description: Hand holding intervention will be performed by the person the patient prefers. Before the continuous passive movement exercise, the person concerned will sit next to the patient\&#39;s bed and warm their hands at a level that will not disturb the patient.1-2 minutes before the continuous passive motion exercise, the patient will hold the patient\&#39;s hand with one hand, without using gloves, with moderate pressure, without rubbing or squeezing to an uncomfortable level.Hand holding intervention will continue until the continuous passive movement exercise is completed.
Study: NCT06606938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Faecal Microbiota Transplantation
Description: FMT at baseline, week 2, week 4

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: Placebo at baseline, week 2, week 4
Study: NCT06606821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Investigational drug will be administered as a sc. injection once-weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.
Study: NCT06607029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the opioid-based control group
Description: Intraoperative analgesia will be administered with conventional opioid drugs such as sufentanil and remifentanil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the opioid-free anesthesia group
Description: The patients will be administered with an opioid-free strategy during surgery. The investigator will use esketamine, dexmetopidine, and local anesthesia to control perioperative pain.
Study: NCT06607419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Recruited patients will receive Blinatumomab since day 29 of induction for 14 days.
Study: NCT06606652

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Acute caffeine intake (3 mg/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Acute caffeine intake (3 mg/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute placebo intake (3 mg/kg of maltodextrin)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute placebo intake (3 mg/kg of maltodextrin)
Study: NCT06606522

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical model
Description: Clinical model: a clinical model based on basic demorgraphic information and commonly executed laboratory tests to differentiate different pathological types of intrinsic AKD.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical model
Description: Clinical model: a clinical model based on basic demorgraphic information and commonly executed laboratory tests to differentiate different pathological types of intrinsic AKD.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary biomarkers
Description: Urinary biomarkers: biomarkers help differentiate different pathological types of intrinsic AKD.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary biomarkers
Description: Urinary biomarkers: biomarkers help differentiate different pathological types of intrinsic AKD.
Study: NCT06604910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: branched chained amino acid
Description: patients undergoing branched chained amino acid
Study: NCT05403593

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention, prospective data collection
Study: NCT05092763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT4SURGERY
Description: The Fit4Surgery intervention consists of the FitBit Inspire HR device, the Fit4Surgery mobile app, and weekly coaching calls. Patients are asked to wear the Fitbit through the entire 9-12 weeks in which they are receiving neoadjuvant chemotherapy both when asleep and when awake. Patients are taught how to understand the Fitbit outputs on the application, for example, understanding how to monitor their steps and heart rate. Caregivers are also be encouraged to assist patients. Patients are provided with information about the benefits of physical activity and effective behavior change strategies for incorporating physical activity into their daily lives. These include things such as short bouts of activity by walking around the room during commercial breaks or planning to be dropped off a short walk from a destination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle Control
Description: Participants assigned to this study arm are instructed to go about their usual activities and receive education about physical activity and a healthy lifestyle for ovarian cancer patients. They are encouraged to download the free Cancer.Net mobile app and visit the cancer.net website for educational materials related to ovarian cancer and survivorship. At the end of the 9-12 week intervention, participants in the Healthy Lifestyle group receive a Fitbit for their optional, personal use after surgery.
Study: NCT05967741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythritol
Description: Erythritol is a naturally occurring and non-nutritive sugar alcohol that is classified as generally recognized as safe (GRAS)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aspartame
Description: Aspartame consists of two amino acids, phenylalanine and aspartic acid, and a methyl group. It does not have metabolic effects and has served as the blinded control beverage in the investigators' completed NIH-funded clinical trials.
Study: NCT04309877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline ER
Description: Capsules of theophylline ER

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline ER
Description: Capsules of theophylline ER

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PO placebo
Description: Capsules of methylcellulose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PO placebo
Description: Capsules of methylcellulose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS)
Description: Purified bacterial wall component as an inflammatory challenge

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS)
Description: Purified bacterial wall component as an inflammatory challenge

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: Normal (0.9%) saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV placebo
Description: Normal (0.9%) saline
Study: NCT05258578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-CBT
Description: The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and problem solving and challenging negative thoughts. Participants are encouraged to complete CBT homework between sessions (i.e., completing food records, pleasurable activities and worksheets).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Resources
Description: Participants will be directed to the CAMH COVID-19 Self-Help webpage (www.camh.ca/covid19) to access coping tools to help with COVID-19 associated stress and anxiety, loss, grief and healing, stigma, and physical isolation.
Study: NCT06379958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leramistat 40mg
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leramistat 40mg
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leramistat 40mg
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leramistat 40mg
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 200 mg
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin 100 Mg Oral Capsule
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Upadacitinib 15 MG
Description: Oral Capsule
Study: NCT05209802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A: High intensity exercise training
Description: Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B: moderate intensity exercise training
Description: Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
Study: NCT06508125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-cross-linked hyaluronic acid
Description: non-cross-linked hyaluronic acid injection with physical therapy
Study: NCT04807647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orhan OSMAN's track Don't Let Your Baby Cry in the Kolik album will be played on the music player.
Description: white noise will be played while breastfeeding
Study: NCT04779554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C, flat dose 40 mg
Description: Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two flat doses. Dose 1 will be 30mg at minute 0 and dose 2 will be 10 mg at minute 60.
Study: NCT05340868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pill
Description: Oral semaglutide treatment
Study: NCT05619081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWERNAP
Description: POWERNAP of max 30min while participants ly down comfortably
Study: NCT06131697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie Exercises without Mulligan Mobilization
Description: McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie Exercises with Mulligan Mobilization
Description: McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.~Along McKenzie exercises Sustained Natural Apophyseal Glide will be given with the tip of thumb placed at an angle of 45° along the eyeball direction reinforced by another thumb. This exercise will be performed for three sets of six repetitions twice a week for the time period of four weeks.
Study: NCT05412654

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High potassium water
Description: High potassium water Potassium 6.2 mg/100ml

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control low potassium water
Description: Control water Potassium 0.2 mg/100ml
Study: NCT05527808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2,intravenous injection ,Q3W 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-platemum
Description: 60-75mg/m2 ,intravenous injection ,Q3W 2-4 cycles
Study: NCT06245330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-001
Description: liquid formulation for Intravenous infusion
Study: NCT04779554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C, weight-based dose 12.5 mg/m2
Description: Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two weight-based doses of 9 mg/m2 at minute 0 and 3 mg/m2 at minute 60.
Study: NCT05769257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IS-001
Description: Intravenous injection of IS-001 investigational drug
Study: NCT06398119

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Treatment Program
Description: Traditional Treatment Program for improving hand function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Treatment Program
Description: Traditional Treatment Program for improving hand function

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Program
Description: Virtual Reality Program for improving hand function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Program
Description: Virtual Reality Program for improving hand function
Study: NCT06006013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study: NCT05236569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: The tranexamic acid injection was given intradermally to the facial skin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection Water
Description: The 0.9% normal saline injection was given intradermally to the facial skin
Study: NCT05145452

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish-oil derived n-3 polyunsaturated fatty acids
Description: 4.2 g/d (7 pills with 600 mg each)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish-oil derived n-3 polyunsaturated fatty acids
Description: 4.2 g/d (7 pills with 600 mg each)
Study: NCT05527808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: or carboplatin
Description: AUC(4-5) ,intravenous injection ,Q3W 2-4 cycles
Study: NCT06006013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06556654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRBR Device
Description: The GORE® Tissue Reinforcement for Breast Reconstruction device is intended to reinforce the soft tissue surrounding the tissue expander in preparation for the breast implant in post-mastectomy breast reconstruction
Study: NCT05261360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF-MSC-EX
Description: Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF-MSC
Description: Intra-articular administration of synovial fluid-derived mesenchymal stem cells
Study: NCT05295043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (CDK)4/6 inhibitor
Description: CDK4/6 inhibitor + AI/fulvestrant therapy，According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
Study: NCT04998461

Intervention type: BIOLOGICAL
Intervention: urine collection
Description: To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.

Intervention type: BIOLOGICAL
Intervention: urine collection
Description: To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.

Intervention type: BIOLOGICAL
Intervention: urine collection
Description: To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.

Intervention type: BIOLOGICAL
Intervention: urine collection
Description: To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.
Study: NCT06037434

Intervention type: DRUG
Intervention: Captopril Tablets
Description: 0.3mg/kg, tid

Intervention type: DRUG
Intervention: Metoprolol Oral Tablet
Description: 0.2mg/kg, bid

Intervention type: DRUG
Intervention: Spironolactone Tablets
Description: 2-4mg/kg, bid

Intervention type: DRUG
Intervention: Torsemide Tablets
Description: 0.2-0.5mg/mg, bid

Intervention type: DRUG
Intervention: Torsemide Tablets
Description: 0.2-0.5mg/mg, bid

Intervention type: DRUG
Intervention: Potassium citrate powder
Description: 0.06g/kg, tid

Intervention type: DRUG
Intervention: Potassium citrate powder
Description: 0.06g/kg, tid
Study: NCT05436392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Comparison Feedback
Description: USAP anesthesia providers will receive monthly alerts via USAP's smartphone-based practice management application, text message, or email presenting individual-level data on their benzodiazepine administration patterns versus other USAP providers, using data from the USAP clinical and quality data warehouse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Comparison Feedback
Description: USAP anesthesia providers will receive monthly alerts via USAP's smartphone-based practice management application, text message, or email presenting individual-level data on their benzodiazepine administration patterns versus other USAP providers, using data from the USAP clinical and quality data warehouse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Informational Letter
Description: Breif informational letters will be distributed to eligible patients within the 2 weeks prior to surgery. Letters will be produced on USAP letterhead and signed by the USAP Chief Quality Officer. Letter text will state USAP's commitment to brain health and avoiding potentially unnecessary medications for patients undergoing surgery. It will also include a statement encouraging patients to discuss anesthesia plans with their clinicians at the time of surgery to aid tailoring of care to individual needs. Letters will be distributed directly to patients via text link, email, or hard copy as a component of standard pre-operative instructional communications and other educational and patient outreach materials related to clinical care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Informational Letter
Description: Breif informational letters will be distributed to eligible patients within the 2 weeks prior to surgery. Letters will be produced on USAP letterhead and signed by the USAP Chief Quality Officer. Letter text will state USAP's commitment to brain health and avoiding potentially unnecessary medications for patients undergoing surgery. It will also include a statement encouraging patients to discuss anesthesia plans with their clinicians at the time of surgery to aid tailoring of care to individual needs. Letters will be distributed directly to patients via text link, email, or hard copy as a component of standard pre-operative instructional communications and other educational and patient outreach materials related to clinical care.
Study: NCT05627154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Serotonin-reuptake inhibitor commonly used to treat depressive and anxiety disorders.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Serotonin-reuptake inhibitor commonly used to treat depressive and anxiety disorders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation
Description: A NICE recommended psychological intervention for mild to moderate depression. In behavioural activation, the person with depression and the therapist work together to identify the relationships between the activities the person undertakes and their mood. It encourages people to become less mood-dependent when planning activities and doing constructive things that they would usually avoid doing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A lactose-based tablet.
Study: NCT05160220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: 0.5 g dried Psilocybe cubensis mushroom material, 0.8 mg psilocybin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 g dried edible non-psychoactive mushroom material.
Study: NCT05296759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin A
Description: botulinum toxin A injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin oral intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine oral drug intake
Study: NCT06511557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non immersive virtual reality ( xbox kinetic)
Description: Treatment starts with a gentle warm-up i.e. hot pack for 10 minutes and gentle stretching of Quadriceps, hamstrings and calves. Each game was performed for 10 minutes with 1 minute rest between games. 3 sessions Per Weeks for 8 weeks (45 Min per Session) were given. All the exergames target muscles like Hamstring, Quadriceps and calves to improve function of knee joint and reduce pain.~Baseline assessment was done at the start of the session and proper cool down and stretching will be performed at the end of each session to promote flexibility and reduce muscle soreness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinetic chain exercises
Description: Session starts with a gentle warm-up i.e. Hot pack for 10 minutes and gentle stretching. Each exercise is performed in 2 sets, each set of 10 repetitions with 1min rest between sets. 3 sessions Per Weeks for 8 weeks (45 Min Per Session) were given .Kinetic chain exercises involve integrated movements that engage multiple joints and muscle groups \& focus on strengthening muscles like quadriceps, hamstrings, glutes, and calf muscles, improving joint stability, function, and reducing pain. Baseline assessment was done at the start of the session and proper cool down and stretching was performed at the end of each session to promote flexibility and reduce muscle soreness